证券代码：603599 证券简称：广信股份 公告编号：2023-036 关于召开 2023 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年第一次临时股东大会 召开的日期时间：2023 年 9 月 11 日 14 点 00 分 召开地点：广信股份总部大楼三楼 (五) 网络投票的系统、起止日期和投票时间。 安徽广信农化股份有限公司 股东大会召开日期：2023年9月11日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 11 日 至 2023 年 9 月 11 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段 ...

安徽广信农化股份有限公司独立董事 关于第五届董事会第十二次会议相关事项的独立意见 根据《关于在上市公司建立独立董事制度的指导意见》、《上市公司治理准则》、 《上海证券交易所股票上市规则》、《公司章程》、公司《独立董事工作制度》等 有关规定，作为安徽广信农化股份有限公司（以下简称公司）的独立董事，我们 参加了公司第五届董事会第十二次会议，本着实事求是的态度对公司第五届董事 会第十二次会议的相关事项发表独立意见如下： 三、2023 年半年度募集资金存放与使用情况 一、对外担保情况 公司能严格遵循《公司法》等法律法规和《公司章程》的有关规定，严格履 行对外担保的审议程序，严格控制对外担保风险。截止 2023 年 6 月 30 日，公司 没有为控股股东提供担保，也没有为公司子公司以外的其他关联方、任何非法人 单位或个人提供担保，不存在与证监发【2003】56 号文相违背的担保事项。 截止 2023 年 6 月 30 日，公司与控股股东及其他关联方的资金往来能够严格 遵守证监发【2003】56 号文的规定，与关联方之间无非经营性资金往来，不存 在关联方违规占用公司资金的情况。 经核查，本次限制性股票回购注销的事宜符合《 ...

一、审议通过公司《2023年半年度报告及摘要》 监事会对公司 2023 年半年度报告及其摘要进行了认真严格地审核：认为： （1）公司 2023 年半年度报告的内容与格式符合中国证监会和上海证券交易 所的规定，所披露的信息真实、完整地反映了公司上半年的经营情况和财务状况 等事项。报告的编制和审议程序符合法律、法规及《公司章程》和公司内部管理 制度的各项规定。 （2）公司监事会成员没有发现参与 2023 年半年度报告编制和审议的人员有 违反保密规定的行为。 （3）公司监事会成员保证公司 2023 年半年度报告所披露的信息真实、准确、 完整，不存在虚假记载、误导性陈述和重大遗漏，并对其内容的真实性、准确性 和完整性承担个别连带责任。 表决结果：3 票赞成，0 票反对，0 票弃权。 证券代码：603599 证券简称：广信股份 编号：2023-029 安徽广信农化股份有限公司 第五届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏并 对其内容的真实性、准确性和完整性承担个别及连带责任。 安徽广信农化股份有限公司（以下简称"公司"）于 2023 年 8 月 24 ...

（一）审议通过公司《2023年半年度报告及摘要》 证券代码：603599 证券名称：广信股份 公告编号：2023-028 安徽广信农化股份有限公司 第五届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 安徽广信农化股份有限公司（以下简称"公司"）第五届董事会第十二次会 议于 2023 年 8 月 24 日召开。本次会议应参会董事 8 人，实际参会董事 8 人，会 议由公司董事长黄金祥先生主持，符合《公司法》和《公司章程》等的相关规定， 会议合法有效。 二、董事会会议审议情况 内容详见公司 2023 年 8 月 25 日于上海证券交易所网站（www.sse.com.cn） 披露的《安徽广信农化股份有限公司 2023 年半年度报告及摘要》。 表决结果：8 票赞成，0 票反对，0 票弃权。 （二）审议通过《关于公司 2023 年半年度募集资金存放与实际使用情况的 专项报告》 内容详见公司 2023 年 8 月 25 日于上海证券交易所网站（www.sse.com.cn） 披露 ...

证券代码：603599 证券简称：广信股份 编号：2023-030 安徽广信农化股份有限公司 关于 2023 年半年度募集资金存放与实际使用情况的专项报告 经中国证券监督管理委员会证监许可[2015]707 号文核准，本公司于 2015 年 5 月 向社会公开发行人民币普通股股票 47,060,000 股，每股发行价格 16.11 元，募集资金 总额为人民币 758,136,600.00 元，扣除发行费用合计人民币 57,421,900.00 元，募集 资金净额为人民币 700,714,700.00 元。该募集资金已于 2015 年 5 月 8 日到位，上述 资金到位情况经华普天健会计师事务所（特殊普通合伙）会验字[2015]2435 号《验资 报告》验证。 截至 2023 年 6 月 30 日，募集资金当前余额为 0.00 元。 （二）非公开发行股票情况 经中国证券监督管理委员会《关于核准安徽广信农化股份有限公司非公开发行股 票的批复》（证监许可[2017]1429 号文）的核准，公司向特定投资者嘉实基金管理有 限公司、华融证券股份有限公司、富国基金管理有限公司、博时基金管理有限公司、 华商基金管理有限公司 ...

证券代码：603599 证券简称：广信股份 公告编号：2023-034 安徽广信农化股份有限公司 关于为全资及控股子公司申请授信提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 被担保人名称：安徽东至广信农化有限公司、辽宁世星药化有限公司 本次担保金额：本次为安徽东至广信农化有限公司提供的担保金额不超 过 10,000 万元，已实际为其提供的担保余额：0 万元； 本次为辽宁世星药化有限公司提供的担保金额不超过 12,000 万元，已 实际为其提供的担保余额：0 万元； 本次担保是否有反担保:否； 公司无逾期的对外担保。 一、担保情况概述 （一）担保基本情况 1、因经营发展需要，安徽东至广信农化有限公司向工商银行股份有限公司 东至支行申请综合授信不超过人民币 10,000 万元，授信期限一年，由安徽广信 农化股份有限公司（以下简称"公司"）提供最高额连带责任保证担保。 （二）本担保事项履行的内部决策程序。 上述担保事项已经公司第五届董事会第十二次会议审议通过。 二、被担保人基本情况 （一）公司 ...

证券代码：603599 证券简称：广信股份 公告编号：2023-027 安徽广信农化股份有限公司 关于子公司 4 万吨对氨基苯酚项目投产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏并对其内容的真实性、准确性和完整性承担个别及连带责任。 安徽广信农化股份有限公司（以下简称"公司"）全资子公司安徽东至广信 农化有限公司"年产 4 万吨对氨基苯酚项目" 经过前期生产工艺、机器设备的 安装调试，已于近期正式全面投产。项目建成后，进一步夯实公司产业链条，延 伸了氯碱-对（邻）硝基氯化苯等上下游原材料的应用，提升主业竞争力，正式 打通了从光气–精细化工品-医药中间体的链条板块，构筑产业链共生生态，实 现价值升级。 公司"年产 4 万吨对氨基苯酚项目"是经公司第五届董事会第六次会议及 2021 年年度股东大会审议通过，由公司非公开发行募投项目"广信股份 3,000 吨/年吡唑醚菌酯项目" 变更而来，项目总投资 41,254.90 万元。具体信息请 详见公司于 2022 年 4 月 28 日刊登在上海证券交易所网站及指定媒体的公告。 项目建成后，项目所需的水、电、蒸汽等，均依托公司 ...

Financial Performance - The net profit attributable to shareholders of the listed company was CNY 521,213,182.36, representing a decrease of 8.43% year-on-year[19]. - The operating revenue for Q1 2023 was CNY 1,925,991,278.96, down 6.35% from the same period last year[19]. - Basic and diluted earnings per share were both CNY 0.80, down 8.94% year-on-year[19]. - Total operating revenue for Q1 2023 was CNY 1,925,991,278.96, a decrease of 6.34% compared to CNY 2,056,692,232.95 in Q1 2022[42]. - Total operating costs for Q1 2023 were CNY 1,385,356,252.05, down 2.55% from CNY 1,421,754,830.52 in Q1 2022[42]. - The total revenue for the first quarter of 2023 was approximately CNY 1,351.19 million, a decrease from CNY 1,434.89 million in the same period of 2022, representing a decline of about 5.8%[34]. Cash Flow - The net cash flow from operating activities was CNY 161,186,254.65, a significant decline of 78.41% compared to the previous year[19]. - The net cash flow from operating activities for the first quarter of 2023 was CNY 161.19 million, significantly lower than CNY 746.43 million in the first quarter of 2022, indicating a decrease of approximately 78.5%[34]. - The cash inflow from investment activities was CNY 1,704.47 million in the first quarter of 2023, compared to CNY 1,974.45 million in the same period of 2022, reflecting a decline of about 13.7%[34]. - The cash received from the recovery of investments was CNY 1,680 million in the first quarter of 2023, compared to CNY 1,955.76 million in the same period of 2022, reflecting a decrease of approximately 14%[34]. - Net cash flow from investing activities for Q1 2023 was CNY 461,903,204.58, compared to a negative cash flow of CNY -654,422,808.93 in Q1 2022[35]. - Net cash flow from financing activities for Q1 2023 was CNY 127,808,052.84, a decrease from CNY 186,231,655.37 in Q1 2022[35]. - The net increase in cash and cash equivalents for Q1 2023 was CNY 729,531,472.38, compared to CNY 282,174,798.71 in Q1 2022, showing a significant improvement[35]. Assets and Liabilities - In Q1 2023, the company's total assets decreased by 0.94% to CNY 13,720,672,855.10 compared to the end of the previous year[5]. - The total liabilities as of the end of Q1 2023 amounted to CNY 4,359,977,532.14, down from CNY 5,036,599,874.69 at the end of Q1 2022[40]. - The company's equity attributable to shareholders increased by 6.14% to CNY 9,211,002,489.52 compared to the end of the previous year[5]. - The total equity attributable to shareholders was CNY 9,211,002,489.52 in Q1 2023, compared to CNY 8,678,212,706.53 in Q1 2022, reflecting an increase of 6.12%[40]. - Accounts receivable increased by 31.80% due to an increase in sales not yet collected[49]. - Other receivables rose by 38.96% primarily due to the transfer of some prepaid amounts to other receivables[49]. - Short-term borrowings rose from $1.24 billion to $1.37 billion, an increase of approximately 10.5%[53]. - Accounts payable decreased from $1.64 billion to $1.40 billion, a decline of about 14.8%[53]. - Contract liabilities decreased significantly from $437.72 million to $215.38 million, a reduction of approximately 50.8%[53]. - Deferred tax assets decreased from $87.92 million to $75.47 million, a decline of about 14.1%[53]. - The company reported a total non-current liability of $3.51 billion, reflecting a stable financial position[53]. Expenses and Other Income - The financial expenses increased by CNY 114.44 million due to exchange losses from the depreciation of the US dollar against the RMB[8]. - The company reported a fair value change gain of CNY 303.68 million, primarily due to increased investment income from financial products[8]. - Non-recurring gains and losses included CNY 39,332,107.48 from unrelated business activities[21]. - The company reported a total of CNY 296.57 million in other non-operating income and expenses during the reporting period[22]. - The income tax expense for the period was CNY 7.66 million, and the impact on minority interests (after tax) was CNY 625.77 million[22]. Research and Development - Research and development expenses for Q1 2023 were CNY 75,466,202.67, down from CNY 89,267,582.42 in Q1 2022, indicating a reduction of 15.5%[42]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 14,688, with the largest shareholder, Anhui Guangxin Group Co., Ltd., holding 40.58% of the shares[25]. Company Strategy - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the report[34].

Revenue and Profitability - The company's revenue from pesticides reached ¥9,062,370,119.54, with a gross margin of 40.99%, reflecting a year-over-year revenue increase of 63.29%[4] - Revenue from pesticides was ¥5,658,556,112.00, with a gross margin of 42.30%, showing a 68.38% increase in revenue compared to the previous year[4] - Domestic revenue amounted to ¥6,902,689,973.38, with a gross margin of 43.03%, representing a 63.49% increase year-over-year[4] - The total revenue for 2022 reached ¥1,359,845,784.87, a significant increase from ¥673,103,585.92 in 2021, representing a growth of approximately 102%[78] - The net profit for 2022 was ¥1,180,368,854.23, compared to ¥591,868,394.88 in 2021, indicating an increase of about 99%[78] - The comprehensive income for the year amounted to approximately RMB 1.48 billion[37] - The total comprehensive income for 2022 was ¥1,180,368,854.23, compared to ¥591,868,394.88 in 2021, marking a growth of approximately 99%[78] Production and Capacity - The production volume of pesticides and intermediates was 310,432.51 tons, with a sales volume of 303,657.16 tons, indicating a 72.26% increase in sales compared to the previous year[5] - A new production line with a capacity of 100,000 tons/year for ortho-nitrochlorobenzene was successfully put into operation, strengthening the company's position in the pesticide industry[52] - The company has a designed capacity of 36.3 million tons per year for its main pesticides and intermediates, with a capacity utilization rate of 85.51%[135] - The company is currently constructing an additional capacity of 40,000 tons per year for aminophenol, with an investment of approximately RMB 32,953.47 million, expected to be completed in 2023[135] Research and Development - The company has established a research and development center with a team of 359 personnel, accounting for 13.82% of the total workforce[27] - The company has developed and mastered multiple production technologies, including DAP/HAP impurity control technology and thiocyanate reaction technology, holding several patents[21] - The company aims to enhance its technological capabilities through ongoing research and development initiatives[78] - The company has implemented advanced synthesis techniques in its production processes, significantly improving product quality and reducing harmful impurities[128] Market Position and Strategy - The company plans to expand its product offerings and improve supply chain capabilities to strengthen its market position[15] - The company aims to enhance its market presence in the agricultural chemicals sector, focusing on sustainable development and high-efficiency low-toxicity products[73] - The company aims to expand its global business footprint by exploring overseas markets and increasing global registration investments[52] - The company has established long-term stable partnerships with renowned clients such as DuPont and FMC, which supports continuous business growth[22] Financial Performance and Investments - The total cash received from sales of goods and services in 2022 was approximately RMB 5.33 billion, compared to RMB 3.14 billion in 2021, indicating a significant increase[32] - Cash flow from operating activities for 2022 was ¥2,927,988,016.26, up from ¥1,410,612,292.25 in 2021, reflecting an increase of approximately 107%[83] - The company reported cash and cash equivalents at the end of 2022 amounting to ¥2,893,073,050.29, an increase from ¥2,259,071,354.55 at the end of 2021, which is a growth of about 28%[85] - The company reported a significant increase in profitability due to strong domestic and international market demand and rising raw material prices[58] Acquisitions and Partnerships - The company acquired a 70% stake in Liaoning Shixing Pharmaceutical Chemical Co., Ltd. for ¥210 million, completed on June 1, 2022[12] - The company completed the acquisition of its subsidiary, Liaoning Shixing Pharmaceutical, enhancing its integrated strategy and diversifying its product structure[52] - Future acquisitions and mergers will be considered to enrich the product line and enhance market share[192] Supply Chain and Procurement - The company has a procurement strategy that focuses on order-driven purchasing to mitigate raw material price fluctuations, with key suppliers located in several provinces[119] - The company has a rigorous supplier qualification process, ensuring that new suppliers meet quality and capability standards before being approved[120] Regulatory and Compliance - The company’s financial statements comply with accounting standards, reflecting its financial position and operating results accurately[149] - The company’s consolidated financial statements reflect the overall financial status and cash flows of the entire corporate group[164] Talent and Human Resources - The company emphasizes the importance of attracting and retaining talent to drive its development[190] - The company has a strong focus on technological innovation, with a dedicated committee led by the chairman to oversee development and innovation efforts[125]

证券代码：603599 证券简称：广信股份 公告编号：2023-015 安徽广信农化股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责 任。 重要内容提示： 会议召开时间：2023 年 04 月 28 日(星期五) 上午 11:00- 12:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 25 日(星期二) 至 04 月 27 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 guangxinzq@chinaguangxin.com 进行提问。公司将在 说明会上对投资者普遍关注的问题进行回答。 安徽广信农化股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日发布公司 2022 年度报告，为便于广大投资者更全面深入 地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 ...